Introduction
RS, cancers, breast cancer, Breast cancer, luminal breast cancer
CANCERS, RECURRENCE, NODE-NEGATIVE BREAST CANCER, BREAST CANCER, BREAST CANCER
Breast cancer is one of the most commonly diagnosed cancers worldwide [The St. Gallen conference in 2007 recommended ET alone and CT followed by ET for patients with highly or incompletely endocrine-responsive and HER2−, intermediate-risk breast cancer [Recurrence score (RS), determined by a 21-gene signature, shows promise for identifying high-risk patients among patients with luminal breast cancer. The TAILORx study showed that adjuvant ET and chemoendocrine therapy had similar efficacies in postmenopausal women with ER+, HER2−, axillary node-negative breast cancer who had a mid-range RS, excluding patients aged ≤ 50 years [We therefore conducted a randomized phase III study (NEOS) to assess the long-term prognosis of patients with ER+EBC treated with neoadjuvant ET (NET) with/without adjuvant CT [